Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Self-administration of Subcutaneous Elranatamab in the Patients' Homes
NCT06015542Phase 2Recruiting
- Start
- Jan 2025
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of elranatamab in multiple myeloma (MM). Started Jan 2025; status: recruiting.
02
Drugs
elranatamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06015542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06015542.